Fonterra’s Breakthroughs in Infant Milk Nutrition
The company announced results of three clinical trials on immune health ingredients and children and infants.
Fonterra (Auckland, New Zealand) announced three new developments with its infant nutrition ingredients at the XVI Congress of Paediatricians held in Moscow last month. The multinational dairy co-op presented results of three clinical trials on various dairy-format ingredients.
In a clinical study on Fonterra’s “complex dairy lipids,” infants consuming formula with these lipids showed improvement in cognitive development, compared to infants consuming a standard infant formula. Fonterra’s complex lipids previously demonstrated activity against rotavirus diarrhea, which affects an estimated 95% of children within their first five years of life.
A second study, to be published in the journal Clinical and Experimental Allergy, featured 425 infants consuming placebo or DR20, Fonterra’s Lactobacillus rhamnosis HN001 probiotic strain. After two years of supplementation, infants in the DR20 group showed reduced prevalence of the skin allergy eczema (atopic dermatitis) by 45%, compared to placebo. After four years of follow-up, the DR20 group continued to show a lower prevalence of eczema.
Lastly, Fonterra offered up the results of a recent human clinical trial on infant formula with its DR10 probiotic strain (Bifidobacterium animalis subspecies lactis HN019) and a prebiotic galactooligosacharide (GOS). The probiotic- and GOS-enriched infant formula was linked to reduced risks of several childhood morbidities (e.g. dysentery, pneumonia, and severe-acute lower respiratory infections) compared to placebo milk in a trial of 312 children.
The Nutritional Outlook Podcast Episode 34: Demystifying Prebiotics and Postbiotics
September 30th 2024In this episode of the Nutritional Outlook Podcast we are looking back on a webcast Nutritional Outlook hosted in May, called “Demystifying the Prebiotic and Postbiotic Markets.” During that event, Sandra Saville, director of education and communication for the International Probiotics Association and Dr. Jessica A. Younes, scientific director of the International Probiotics Association debunked myths about prebiotic and postbiotics, and defined the respective categories to help manufacturers better understand how to responsibly formulate and market prebiotic and postbiotic products.
Balchem’s Newest Launch Optifolin⁺® Brings Innovation to the Folate Market
September 19th 2024Supplement launches featuring 5-MTHF are on the rise with double digit growth. In this episode of Nutritional Outlook’s podcast, we explore Optifolin⁺, a new ingredient in the market that offers essential nutrition from prenatal through adulthood. Join us as we uncover the potential impact of the next evolution in folate, setting the stage for a healthier future.
